BridgeMD
New treatment option for Melanoma
Official title Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients
ClinicalTrials.gov ID: NCT05029791
What this study is testing
- What it's testing
- COLEMAN is an opened prospective monocentric non-randomized study, initiated by the Hospices Civils de Lyon. Population targeted are patients from 18 years old with stage III or IV metastatic melanoma eligible for a metastatic melanoma treatment administered as part of usual care.
- Time commitment: about 5 years
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient age ≥ 18
- Female patients must agree to the use of 2 methods of contraception. For man one method of contraception is needed if if his partner is in...
- Patients with metastatic stage III or IV melanoma relapse
- Eligible for a melanoma metastatic treatment indicated and administered as part of usual care
- Patients must be willing and able to undergo cutaneous tumor biopsies (except on the face and folds or lymph node) according to the study protocol
You likely can't join if
- Hematologic tumours under treatment
- Patients with a documented history of autoimmune pathology
- Ocular melanoma
- Persons placed under the safeguard of justice
- Use of immunosuppressants including corticosteroids 4 weeks before the inclusion
See the full eligibility criteria
- Patient age ≥ 18
- Female patients must agree to the use of 2 methods of contraception. For man one method of contraception is needed if if his partner is in childbearing age throughout the study and for at least 5 months after last study...
- Patients with metastatic stage III or IV melanoma relapse
- Eligible for a melanoma metastatic treatment indicated and administered as part of usual care
- Patients must be willing and able to undergo cutaneous tumor biopsies (except on the face and folds or lymph node) according to the study protocol
- Patient insured or beneficiary of a health insurance plan
- Patient able to provide informed consent and sign approved consent forms to participate in the study
- Patient accepting the conservation of biological samples and their use for clinical research including genetic research
- Hematologic tumours under treatment
- Patients with a documented history of autoimmune pathology
- Ocular melanoma
- Persons placed under the safeguard of justice
- Use of immunosuppressants including corticosteroids 4 weeks before the inclusion
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.